Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis

Harrington, J. Timothy; Ste-Marie, Line; Brandi, Maria Luisa; Civitelli, Roberto; Fardellone, Patrice; Grauer, Andreas; Barton, Ian; Boonen, Steven

doi:10.1007/s00223-003-0042-4

Cited by 198 publications

(115 citation statements)

References 38 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…There are two fundamentally, distinct components of the mechanism of action of nitrogen containing bisphosphonates (N-BPs) [19,20]: These are 1) binding to the bone, and 2) binding to and inhibition of a key osteoclast enzyme farnesyl pyrophosphate synthase (FPPS). Regarding the oral bisphosphonates, only Risedronate and Alendronate have been proven to reduce vertebral and hip fracture risk in clinical trials [8][9][10][11][12][13][14][15][21][22][23][24]. Zoledronate is an intravenous bisphosphonate therapy and has also been proven to reduce vertebral and hip fracture risk in clinical trials.…”

Section: Bisphosphonates Are the Most Common Therapy For Osteoporosismentioning

confidence: 99%

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ringe

Möller

2009

Rheumatol Int

View full text Add to dashboard Cite

Section: Bisphosphonates Are the Most Common Therapy For Osteoporosismentioning

confidence: 99%

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ringe

Möller

2009

Rheumatol Int

View full text Add to dashboard Cite

“…In those analyses, reduction of nonvertebral fractures began at 6 months of risedronate therapy and at 12 months of alendronate therapy. At 12 months, reductions in nonvertebral fractures were 74% with risedronate [37] and 47% with alendronate [38]. Risedronate has also been shown to decrease clinical vertebral fractures by 69% [39] compared to 59% [40] with alendronate at 12 months.…”

Section: Discussionmentioning

confidence: 98%

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Grima¹,

Παπαϊωάννου

Thompson³

et al. 2007

Osteoporos Int

View full text Add to dashboard Cite

Summary-The RisedronatE and ALendronate (REAL) study provided a unique opportunity to conduct cost-effectiveness analyses based on effectiveness data from real-world clinical practice. Using a published osteoporosis model, the researchers found risedronate to be cost-effective compared to generic or brand alendronate for the treatment of Canadian postmenopausal osteoporosis in patients aged 65 years or older.

show abstract

“…Fracture protection occurs within a few months of beginning therapy (10,12,(22)(23)(24) and is sustained for at least several years (19,25). Importantly, the cycle of progressive, multiple vertebral fractures is reduced by 77-96% (10,18,20).…”

Section: Skeletal Effects Of Bisphosphonatesmentioning

confidence: 99%

Bisphosphonates

McClung

2006

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve bone structure, improve bone strength and, in patients with osteoporosis, substantially reduce fracture risk. They are effective in multiple clinical settings including postmenopausal osteoporosis, low bone mass in men and drug-induced bone loss. Intermittent oral dosing and intravenous administration are more convenient than the original daily dosing regimen. These drugs are generally well tolerated and have an excellent safety profile in that serious side effects are uncommon. Potent bisphosphonates are generally the preferred treatment option for most patients with or at risk for osteoporosis. RESUMO Bisfosfonatos.Osteoporose é o resultado da perda óssea devida a um imbalanço no turnover ósseo, onde a reabsorção óssea excede sua formação. Os bisfosfonatos são inibidores potentes da atividade osteoclástica, que reduzem o turnover ósseo e restabelecem o balanço entre a reabsorção e a formação óssea. Em estudos clínicos, vários bisfosfonatos previnem a perda óssea, preservam sua estrutura, melhoram sua força e substancialmente reduzem o risco de fraturas em pacientes com osteoporose. Eles são efetivos em várias situações clínicas, incluindo a osteoporose pós-menopáusica, a reduzida massa óssea em homens e perda óssea induzida por drogas. Doses orais intermitentes e administração intravenosa são mais convenientes do que o esquema original de doses diárias. Essas drogas são geralmente bem toleradas e têm um excelente perfil de segurança, no qual efeitos colaterais sérios são incomuns. Os bisfosfonatos potentes são geralmente a opção terapêutica preferida para a maioria dos pacientes com ou em risco de osteoporose. O STEOPOROSIS IS A DISORDER of skeletal fragility due a combination of low bone mass, deteriorated bone architecture and perhaps alterations in other aspects of bone quality (1). Osteoporosis is usually the result of bone loss that occurs after menopause in women and in older men and women. This bone loss is a consequence of increased and unbalanced bone review article Bisphosphonates

show abstract

Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis

Cited by 198 publications

References 38 publications

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Bisphosphonates

Contact Info

Product

Resources

About